OSSIANIX, INC is a privately held pre clinical company that develops Biotherapeutic products using the highly versatile single domain VNAR antibody from the shark. The attractive biological and biophysical properties of the VNAR structure allows the rapid delivery of exquisitely high-affinity products to multiple target classes that have proven difficult or impossible by standard antibody approaches or alternative scaffolds.
The company is headquartered in the University City Science Center in downtown Philadelphia and has research laboratories at the Stevenage Bioscience Catalyst in Stevenage, Herts, UK. Ossianix was founded by Frank S Walsh, Corey Goodman and Lynn Rutkowski who have had distinguished careers in academia, Pharma and Biotech and bring a wealth of experience to the problem of delivering the next generation of Biologics products. The company started operations in 2012 with funding from Lundbeck Pharmaceuticals, BioAdvance and the ALS Association. Current programs focus on neurodegereration, neurooncology, ALS, pain and botulism.
Location: United States, Pennsylvania, Philadelphia
Member count: 11-50
Founded date: 2012
Investors 1
| Date | Name | Website |
| - | BioAdvance | bioadvance... |
Mentions in press and media 3
| Date | Title | Description | Category | Author | Source |
| 08.01.2014 | Shark mode... | Ossianix CEO Frank Walsh told ... | - | - | medcitynew... |
| 03.01.2012 | Ossianix R... | Ossianix, Inc., a Philadelphia... | funding U... | - | finsmes.co... |
| - | Shark mode... | Two years after securing strat... | - | - | medcitynew... |